Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 166

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 5
Chunk 166
---
.S. launch of AlphaID™ At Home, an innovative solution to detect alpha-1 deficiency, a genetic disease whose symptomology is similar to COPD and (2) the launch of our CD38 solution, the first soluble recombinant protein to facilitate pre-transfusion compatibility testing in patients with multiple myeloma.
Bio Supplies. Net revenue from Bio Supplies increased by 9.5% (11.3% at constant currency), from €146.1 million in 2022 to €160.0 million in 2023, mainly due to the continued integration of our subsidiary Access Biologicals (acquired in 2022), which expanded the product portfolio of this business unit, and by sales of hyperimmune plasma to third parties.
Others. Net revenue from Others decreased by 18.7% from €250.2 in 2022 to €203.5 million in 2023 (though at constant currency this represented a 4.0% increase). This decrease was due to the sale of certain companies and assets formerly part of our hospital division, a business unit that we shut down in 2022.
The following table reflects a summary of net revenue by each of our geographic regions for 2023 as compared to 2022:

               ​                   ​         ​          ​           ​           ​          ​          ​          ​         ​       ​      ​          ​        ​
---------------------------------------------------------------------------------------------------------------------------------------------------------------
​                                  ​      Year ended   ​      ​                ​        Year ended   ​      ​             ​      ​       ​      ​              
​                                  ​    December 31,   ​      % of total net   ​      December 31,   ​      % of total    ​      ​       ​      ​              
Summary of Net Revenue by Region   2023                       revenue          2022                         net revenue          % var          % var CC(1)    
​                                  ​                                                                        (in thousands of euros, except for percentages)    
European Union(2)                          1,255,927   19.1                    %         1,032,210   17.0                 %      21.7    %      21.7          %
United States and Canada                   3,898,961   59.1                    %         3,855,607   63.6                 %      1.1     %      3.4           %
Rest of the World                          1,437,089   21.8                    %         1